This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Ross, C Articles by Bendtzen, K Search for Related Content PubMed PubMed Citation Articles by Ross, C Articles by Bendtzen, K Pubmed/NCBI databases Substance via MeSH Social Bookmarking                         What's this?

Measuring and evaluating interferon b-induced antibodies in patients with multiple sclerosis

Institute for Inflammation Research, Rigshospitalet University Hospital, Copenhagen

K M Clemmesen

Institute for Inflammation Research, Rigshospitalet University Hospital, Copenhagen

P S Sørensen

Department of Neurology, Rigshospitalet University Hospital, Copenhagen

N Koch-Henriksen

Aalborg Hospital, Ålborg, Department of Neurology, Denmark

K Bendtzen

Institute for Inflammation Research, Rigshospitalet University Hospital, Copenhagen

Author for correspondence: Klaus Bendtzen, Institute for Inflammation Research IIR 7521, Rigshospitalet University Hospital, 9 Blegdamsvej, DK-2100 Copenhagen, Denmark. E-mail: address: kben@mail.dk Administration of interferons (IFNs) may induce antibodies that interfere with therapeutic efficacy. We have optimized and validated methods for large-scale economic screening. Sera from patients with relapsing-remitting multiple sclerosis (MS) were investigated for binding antibody (BAb) by protein-G affinity-chromatography radioimmunoassay and a commercially available enzyme immunoassay (EIA). Neutralizing antibody (NAb) was investigated by cytopathic effect assays (CEA) using both fixed amount and serially diluted sera. BAb correlated with log10-transformed titres obtained by EIA (r=0.70, p<0.0001); the latter, however, failed to demonstrate low-level BAb. Comparison of clinical significance of NAb-positivity measured by biological assays with different sensitivities demonstrated an optimal odds ratio for relapse rate using 10 laboratory units (LU)/mL. Purification of IgG prior to CEA removed toxicity from toxic sera. The neutralizing capacity data correlated linearly with log10-transformed titres obtained by a Kawade 10-to-1 LU/mL CEA (r=0.77, p<0.0001). In conclusion, neutralizing capacity CEA utilizing a fixed amount of serum predicts differences in relapse rates in IFNß-treated MS patients and correlates with NAb titres of the 10-to- 1 LU/mL CEA. Neutralizing capacity CEA is less laborious and more economical than titre-based NAb assays and suitable for large-scale screenings of MS patients.

Key Words: binding antibodies • clinical validation • multiple sclerosis • neutralizing antibodies • radioimmunoassay • screening methods • therapeutic use • type 1 interferon

Multiple Sclerosis, Vol. 12, No. 1, 39-46 (2006)
DOI: 10.1191/1352458506ms1272oa


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				D. Hesse, F. Sellebjerg, and P. S. Sorensen Absence of MxA induction by interferon {beta} in patients with MS reflects complete loss of bioactivity Neurology, August 4, 2009; 73(5): 372 - 377. [Abstract] [Full Text] [PDF]

				M Ravnborg, K Bendtzen, O Christensen, P. Jensen, D Hesse, M. Tovey, and P. Sorensen Treatment with azathioprine and cyclic methylprednisolone has little or no effect on bioactivity in anti-interferon beta antibody-positive patients with multiple sclerosis Multiple Sclerosis, March 1, 2009; 15(3): 323 - 328. [Abstract] [PDF]

				L. van der Voort, A Kok, A Visser, C. Oudejans, M Caldano, F Gilli, A Bertolotto, C. Polman, and J Killestein Interferon-{beta} bioactivity measurement in multiple sclerosis: feasibility for routine clinical practice Multiple Sclerosis, February 1, 2009; 15(2): 212 - 218. [Abstract] [PDF]

				P. Soelberg Sorensen Review: Neutralizing antibodies against interferon-beta Therapeutic Advances in Neurological Disorders, September 1, 2008; 1(2): 125 - 141. [Abstract] [PDF]

				C Gneiss, M Brugger, A Millonig, A Fogdell-Hahn, D Rudzki, J Hillert, T Berger, M Reindl, and F Deisenhammer Comparative study of four different assays for the detection of binding antibodies against interferon-{beta} Multiple Sclerosis, July 1, 2008; 14(6): 830 - 836. [Abstract] [PDF]

				N. Garg, B. Weinstock-Guttman, K. Bhasi, J. Locke, and M. Ramanathan An association between autoreactive antibodies and anti-interferon-{beta} antibodies in multiple sclerosis Multiple Sclerosis, August 1, 2007; 13(7): 895 - 899. [Abstract] [PDF]

				P. Sorensen, N. Koch-Henriksen, and K. Bendtzen Are ex vivo neutralising antibodies against IFN-{beta} always detrimental to therapeutic efficacy in multiple sclerosis? Multiple Sclerosis, June 1, 2007; 13(5): 616 - 621. [Abstract] [PDF]

				R. A Farrell and G. Giovannoni Measuring and management of Anti-Interferon Beta Antibodies in subjects with Multiple Sclerosis Multiple Sclerosis, June 1, 2007; 13(5): 567 - 577. [Abstract] [PDF]

				F Gilli, F Hoffmann, A Sala, F Marnetto, M Caldano, P Valentino, L Kappos, A Bertolotto, and R L. Lindberg Qualitative and quantitative analysis of antibody response against IFN{beta} in patients with multiple sclerosis Multiple Sclerosis, November 1, 2006; 12(6): 738 - 746. [Abstract] [PDF]

				B. Petersen, K. Bendtzen, N. Koch-Henriksen, M. Ravnborg, C. Ross, P. S. Sorensen, and The Danish Multiple Sclerosis Group Persistence of neutralizing antibodies after discontinuation of IFN{beta} therapy in patients with relapsing-remitting multiple sclerosis Multiple Sclerosis, June 1, 2006; 12(3): 247 - 252. [Abstract] [PDF]